Multiple Myeloma

The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.

The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.

Jesús Berdeja, MD, discusses how CELMoDs such as iberdomide and mezigdomide may reshape standard-of-care treatment in multiple myeloma.

The top 5 OncLive TV videos of the week.

The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.

Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.

Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.

The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.

Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.

The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.

The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.

After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.

Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.

Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across 2 cevostamab dose levels, supporting selection of a recommended phase 3 regimen.

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

Ja Min Byun, MD, PhD, discusses updated phase 1 findings with mezigdomide plus elranatamab in relapsed/refractory multiple myeloma.

The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.

CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.

The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.